The company raised $54.5 million to make treatments that restore protein function in polycystic kidney disease ...

Hundreds of children and adults with rare forms of cystic fibrosis in England will be able to access “life-changing” new ‘triple-combination’ therapy for the very first time, the NHS has announced.

Hundreds of people with cystic fibrosis are to be offered a once-a-day pill which has been hailed as “life changing” by health experts.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Life-changing’ therapy now available for cystic fibrosis patients - The new pill is seen as a ‘major leap forward’ for hundreds of patients living with the rarest forms of cystic fibrosis ...

A uniform high-frequency description is presented for vertex (tip) diffraction at the tip of a pyramid, for source and observation points at finite distance from the tip. This provides an effective ...

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Let’s prioritise function over form and people over polish. By doing so, we’ll not only create a more comfortable and conducive environment for worship, but we’ll also be serving the Ummah ...

"Relative performance was hindered by our position in Vertex, Inc. (NASDAQ:VERX), which furnishes comprehensive tax compliance software to mid-market companies. While Vertex met its revenue targets, ...

Ono will assist with Vertex's clinical trials for povetacicept and handle marketing approvals in Japan and South Korea, focusing on IgAN and pMN with possible additional uses.

BOSTON, June 20, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 ...